Dashboard
Manage Tickers

HCM HUTCHMED (China) Ltd

Nasdaq hutch-med.com


$ 15.17 $ -0.26 (-1.69 %)    

Friday, 17-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 15.14
$ 15.19
$ 14.61 x 2
$ 16.58 x 100
$ 15.01 - $ 15.29
$ 11.51 - $ 21.50
22,889
na
2.64B
$ 1.07
$ 69.95
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hutchmed-highlights-frusica-2-data-at-esmo-2025-showing-605-response-rate-and-promising-outcomes-in-advanced-kidney-cancer
HUTCHMED Highlights FRUSICA-2 Data At ESMO...
10/13/2025 06:17:44

reported-earlier-hutchmed-to-present-new-and-updated-clinical-data-on-fruquintinib-savolitinib-and-surufatinib-at-esmo-congress-2025-in-berlin
Reported Earlier, HUTCHMED To Present New ...
10/02/2025 06:24:10

new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Med...

morgan-stanley-downgrades-hutchmed-china-to-underweight-lowers-price-target-to-1375
Morgan Stanley Downgrades HUTCHMED (China)...
09/22/2025 17:20:15

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the pri...

ibex-tesla-ionq-warner-bros-discovery-and-other-big-stocks-moving-higher-on-friday
IBEX, Tesla, IonQ, Warner Bros. Discovery ...
09/12/2025 14:24:09

reported-earlier-hutchmed-to-present-updated-savolitinib-data-in-nsclc-at-world-conference-on-lung-cancer-2025-including-sachi-and-savannah-studies
Reported Earlier, HUTCHMED To Present Upda...
09/05/2025 06:55:30

reported-sunday-hutchmed-appoints-johnny-cheng-as-acting-chief-executive-officer-following-dr-weiguo-sus-leave-of-absence-for-health-reasons
Reported Sunday, HUTCHMED Appoints Johnny ...
08/25/2025 06:29:22

Core News & Articles
Reported Earlier, HUTCHMED Progresses SANO...
08/20/2025 07:23:34

correction-hutchmed-china-h1-epads-261-up-from-015-yoy-sales-277677m-down-from-305681m-yoy
CORRECTION: HUTCHMED (China) H1 EPADS $2.6...
08/07/2025 11:43:05

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

b-of-a-securities-maintains-buy-on-hutchmed-china-raises-price-target-to-28
B of A Securities Maintains Buy on HUTCHME...
07/22/2025 16:14:52

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $...

hutchmed-receives-china-nmpa-approval-for-orpathys-in-combination-with-tagrisso-for-treatment-of-egfrm-nsclc-patients-with-met-amplification-after-progression-on-egfr-inhibitor-therapy
HUTCHMED Receives China NMPA Approval For ...
06/30/2025 08:53:21

Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum...

Core News & Articles
Reported Earlier, HUTCHMED And Innovent Se...
06/05/2025 07:37:45

reported-sunday-hutchmed-highlights-sachi-phase-iii-data-at-asco-2025-savolitinib-plus-osimertinib-shows-significant-pfs-benefit-in-egfr-nsclc-with-met-amplification
Reported Sunday, HUTCHMED Highlights SACHI...
06/02/2025 06:22:06

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favora...

reported-earlier-hutchmed-to-present-new-data-on-savolitinib-ranosidenib-fruquintinib-and-surufatinib-at-asco-2025
Reported Earlier, HUTCHMED To Present New ...
05/23/2025 06:59:05

reported-earlier-hutchmed-to-present-new-data-on-savolitinib-fruquintinib-and-surufatinib-at-aacr-2025-in-chicago
Reported Earlier, HUTCHMED To Present New ...
04/24/2025 07:25:41

reported-earlier-hutchmed-wraps-enrollment-in-phase-ii-gastric-cancer-trial-for-savolitinib-targets-late-2025-china-filing
Reported Earlier, HUTCHMED Wraps Enrollmen...
04/22/2025 05:33:40

The China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation to savol...

progress-software-posts-upbeat-results-joins-microvast-pvh-and-other-big-stocks-moving-higher-on-tuesday
Progress Software Posts Upbeat Results, Jo...
04/01/2025 14:32:43

hutchmed-announces-that-the-new-drug-application-for-tazverik-tazemetostat-has-been-granted-conditional-approval-in-china-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-with-ezh2-mutation-who-have-received-at-least-two-prior-systemic-therapies
HUTCHMED Announces That The New Drug Appli...
03/21/2025 10:03:27

reported-earlier-hutchmed-presents-savannah-trial-results-for-savolitinib--tagrisso-in-met-driven-nsclc-at-european-lung-cancer-congress
Reported Earlier, HUTCHMED Presents SAVANN...
03/20/2025 07:22:00

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, r...

hutchmeds-oncology-revenue-hits-2715-million-rising-65-on-fruzaqla-strength
Hutchmed's Oncology Revenue Hits $271.5 Mi...
03/19/2025 16:09:45

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and n...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION